Cooling Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke (EuroHYP-1)

This is an interventional treatment trial for Acute Ischemic Stroke focused on measuring acute ischemic stroke, hypothermia Read More

Inclusion Criteria:

• Written informed consent obtained from the patient or his/her legally acceptable representative or under such other arrangements as may be legally established in participating countries
• Patients of both sexes aged ≥18 years
• Estimated body weight of 50 up to and including 120kg
• Diagnosis of acute ischaemic stroke
• Possibility to start therapeutic hypothermia within 6 hours after onset of stroke
• Possibility to start therapeutic hypothermia within 150 minutes after start of alteplase administration in patients receiving thrombolysis at the trial site or within 150 minutes after start of endovascular treatment, if this is later
• Possibility to start therapeutic hypothermia within 150 minutes after admission to trial site in patients not receiving thrombolysis or in patients who have received thrombolysis at a different site
• mRS score ≤2 prior to onset of stroke
• NIHSS score ≥6
• GCS motor response subscale score ≥5

Exclusion Criteria:

• Use of monoamineoxidase inhibitors in the 14 days prior to screening
• Current use of medication interacting with pethidine or buspirone, i.e., ritonavir, phenytoin, cimetidine, phenothiazines, opioids and partial opioid agonists (e.g., pentazocine, nalbuphine, buprenorphine)
• Acute alcohol intoxication
• Opioid addiction
• Nursing mother or pregnant woman, as verified by a positive urine pregnancy test in females of childbearing potential
• Known hypersensitivity to the IMPs or any of their formulation ingredients
• Patient who is imprisoned or is lawfully kept in an institution
• Employee or direct relative of an employee of the CRO (if applicable), the department of the investigator, or the sponsor
• Participation in an interventional clinical trial within the last 4 weeks, or be under the exclusion period from another trial
• Prior participation in this trial
• Any acutely life-threatening conditions other than acute ischaemic stroke
• Rapidly resolving stroke symptoms
• Evidence from CT or MRI of intracranial haemorrhage or tumour or encephalitis or any diagnosis likely to cause the present symptoms other than acute ischaemic stroke. Haemorrhagic transformation of the infarct is not an exclusion criterion, except when there is a parenchymal haematoma covering more than 30% of the infarcted area, with significant space-occupying effect, or when there is a bleeding remote from the infarcted area
• Known convulsive disorder, acute closed angle glaucoma, myasthenia gravis
• SPO2 <94% (as measured by pulse oximetry) under nasal oxygen administration
• Other severe respiratory disorder
• Bradycardia (<40 bpm)
• Severe cardiac failure, defined as NYHA classification ≥III
• Myocardial infarction or angina pectoris in the 3 months prior to screening
• Vasospastic disorders (e.g., Raynaud's disease)
• Haematological dyscrasia (e.g., sickle cell disease, cryoglobulinaemia)
• Known platelet count <100,000/mm3
• Known INR >1.7
• Skin damage (e.g., inflammation, burns, injuries, ulcerations, hives, rash) at the sites intended to be used for cooling
• Clinical diagnosis of sepsis
• Known severe hepatic impairment (serum ALAT and/or ASAT >3 times ULN)
• Known renal impairment (serum creatinine >2mg/100ml)
• Addison's disease
• Any other condition that may interfere with, or be aggravated by, therapeutic hypothermia
• Any condition that is thought to reduce the compliance to cooperate with the trial procedures